Conditions:
Gastrointestinal
Stromal
Tumors;
Small-cell
Lung
Cancer;
Adenoid
Cystic
Carcinoma;
Uveal
Melanoma;
Neuroendocrine
Tumors;
Chromophobe
Renal
Cell
Carcinoma;
Clear
Cell
Renal
Cell
Carcinoma
Interventions:
Drug:
NN3201
Sponsors:
Novelty
Nobility,
Inc.
Recruiting
Feeds
32933 items (32933 unread) in 74 feeds
Acinar Cell Carcinoma
(534 unread)
Acinic Cell Carcinoma
(314 unread)
Adenoid Cystic Carcinoma
(566 unread)
Adrenal Gland Cancer
(2429 unread)
Ampulla Of Vater
(469 unread)
Anal Cancer
(2709 unread)
Angiosarcoma
(990 unread)
Appendix Cancer
(684 unread)
Bile Duct Cancer
(4355 unread)
Brain and CNS
(6120 unread)
Carcinoid
(887 unread)
Endocrine/Neuroendocrine
(5825 unread)
Gall Bladder Cancer
(1132 unread)
Hemangioendothelioma
(1176 unread)
Hepatoblastoma
(770 unread)
Pancreas
(563 unread)
Phyllodes
(384 unread)
PMP and Mucinous Tumors
(477 unread)
Rhabdomyosarcoma
(1118 unread)
Sarcoma
(1431 unread)
Trial - Adenoid Cystic Carcinoma (40 unread)
-
A Study of the C-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced And/or Metastatic Solid Tumors Known to Express C-Kit
Fetched: February 21st, 2025, 3:00am UTC
-
A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers
Fetched: February 21st, 2025, 3:00am UTC
Conditions: Salivary Gland Cancer; Advanced Salivary Gland Carcinoma; Metastatic Salivary Gland Cancer; Adenoid Cystic Carcinoma
Interventions: Drug: Ivonescimab
Sponsors: Glenn J. Hanna; Summit Therapeutics
Not yet recruiting -
Transoral Robotic Surgery in Treating Patients with Benign or Malignant Tumors of the Head and Neck
Fetched: December 2nd, 2024, 3:00am UTC
Conditions: Recurrent Adenoid Cystic Carcinoma of the Oral Cavity; Recurrent Mucoepidermoid Carcinoma of the Oral Cavity; Recurrent Squamous Cell Carcinoma of the Hypopharynx; Recurrent Squamous Cell Carcinoma of the Larynx; Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity; Recurrent Verrucous Carcinoma of the Larynx; Recurrent Verrucous Carcinoma of the Oral Cavity; Stage 0 Hypopharyngeal Cancer; Stage 0 Laryngeal Cancer; Stage 0 Lip and Oral Cavity Cancer; Stage I Adenoid Cystic Carcinoma of the Oral Cavity; Stage I Mucoepidermoid Carcinoma of the Oral Cavity; Stage I Squamous Cell Carcinoma of the Hypopharynx; Stage I Squamous Cell Carcinoma of the Larynx; Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage I Verrucous Carcinoma of the Larynx; Stage I Verrucous Carcinoma of the Oral Cavity; Stage II Adenoid Cystic Carcinoma of the Oral Cavity; Stage II Mucoepidermoid Carcinoma of the Oral Cavity; Stage II Squamous Cell Carcinoma of the Hypopharynx; Stage II Squamous Cell Carcinoma of the Larynx; Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage II Verrucous Carcinoma of the Larynx; Stage II Verrucous Carcinoma of the Oral Cavity; Stage III Adenoid Cystic Carcinoma of the Oral Cavity; Stage III Mucoepidermoid Carcinoma of the Oral Cavity; Stage III Squamous Cell Carcinoma of the Hypopharynx; Stage III Squamous Cell Carcinoma of the Larynx; Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage III Verrucous Carcinoma of the Larynx; Stage III Verrucous Carcinoma of the Oral Cavity; Stage IV Squamous Cell Carcinoma of the Hypopharynx; Stage IVA Adenoid Cystic Carcinoma of the Oral Cavity; Stage IVA Mucoepidermoid Carcinoma of the Oral Cavity; Stage IVA Squamous Cell Carcinoma of the Larynx; Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVA Verrucous Carcinoma of the Larynx; Stage IVA Verrucous Carcinoma of the Oral Cavity; Stage IVB Adenoid Cystic Carcinoma of the Oral Cavity; Stage IVB Mucoepidermoid Carcinoma of the Oral Cavity; Stage IVB Squamous Cell Carcinoma of the Larynx; Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVB Verrucous Carcinoma of the Larynx; Stage IVB Verrucous Carcinoma of the Oral Cavity; Stage IVC Adenoid Cystic Carcinoma of the Oral Cavity; Stage IVC Mucoepidermoid Carcinoma of the Oral Cavity; Stage IVC Squamous Cell Carcinoma of the Larynx; Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity; Stage IVC Verrucous Carcinoma of the Larynx; Stage IVC Verrucous Carcinoma of the Oral Cavity; Tongue Cancer
Interventions: Procedure: transoral robotic surgery; Procedure: quality of life assessment
Sponsors: Ohio State University Comprehensive Cancer Center
Recruiting -
Agnostic Therapy in Rare Solid Tumors
Posted: October 14th, 2024, 11:00pm UTC
Conditions: Urachal Cancer; Parathyroid Carcinoma; Fibrolamellar Carcinoma; Angiosarcoma; Secretory Carcinoma of Breast; Anal Neoplasms; Metaplastic Breast Carcinoma; Translocation Renal Cell Carcinoma; Carcinosarcoma; Small Intestine Neoplasms; Cholangiocarcinoma; Sertoli-Leydig Cell Tumor; Adenoid Cystic Carcinoma; Mesothelioma; Neuroblastoma; Adrenal Gland Neoplasms; Penile Neoplasms; Apocrine Carcinoma; Fibrosarcoma; Cancer of Unknown Primary; Hemangioblastoma; Thyroid Neoplasms; Hepatoblastoma; Fallopian Tube Neoplasms; Leiomyosarcoma; Vaginal Neoplasms; Neurofibrosarcoma; Gallbladder Neoplasms; Osteosarcoma; Biliary Tract Neoplasms; Clear Cell Endometrial Cancer; Yolk Sac Tumor; Vulvar Neoplasms; Kaposi Sarcoma; Ovarian Epithelial Cancer; Soft Tissue Sarcoma; Urethral Neoplasms; Granulosa Cell Tumor; Primitive Neuroectodermal Tumor; Neuroendocrine Tumors; Trophoblastic Tumor
Interventions: Drug: Nivolumab
Sponsors: Instituto do Cancer do Estado de São Paulo; Financiadora de Estudos e Projetos
Recruiting -
Descriptive Cohort of French Patients Treated With Carbonetherapy Since October 2010 Outside PHRC-ETOILE
Posted: August 2nd, 2024, 11:00pm UTC
Conditions: Cancer; Cystic Carcinomas, Adenoid; Soft-tissue Sarcomas; Rhabdomyosarcoma Pleomorphic; Sarcoma,Soft Tissue; Osteosarcomas; Chondrosarcoma, Grade 3; Chordoma; Angiosarcomas
Interventions: Other: Questionnaire
Sponsors: Hospices Civils de Lyon; Centre François Baclesse, Centre de lutte contre le cancer (CLCC)
Not yet recruiting -
An Investigational Scan (Ga-68 PSMA-11 PET/CT) for the Detection of Therapy Response in Patients With Metastatic Adenoid Cystic Carcinoma
Posted: July 26th, 2024, 11:00pm UTC
Conditions: Metastatic Adenoid Cystic Carcinoma
Interventions: Procedure: Computed Tomography; Other: Electronic Health Record Review; Drug: Ga-68 PSMA-11; Procedure: Positron Emission Tomography
Sponsors: Mayo Clinic
Enrolling by invitation -
Study of Safety and Efficacy of RGT-61159 in Adults With Relapsed/Refractory Adenoid Cystic Carcinoma (ACC) or Colorectal Carcinoma (CRC)
Posted: June 17th, 2024, 11:00pm UTC
Conditions: Adenoid Cystic Carcinoma; Colorectal Cancer
Interventions: Drug: RGT-61159
Sponsors: Rgenta Therapeutics Inc
Recruiting -
177Lu-PSMA (177Lu-PNT2002) in PSMA-Positive Adenoid Cystic Carcinoma
Posted: March 21st, 2024, 11:00pm UTC
Conditions: Adenoid Cystic Carcinoma
Interventions: Drug: 177Lu-PNT2002
Sponsors: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Adenoid Cystic Carcinoma Research Foundation; Progenics Pharmaceuticals, Inc.
Not yet recruiting -
The Evaluation of the Effectiveness, Safety and Tolerability of Treatment, Using a PSMA-Lu177, in Patients With ACC- an Open, Non-commercial Clinical Trial
Posted: January 10th, 2024, 1:00am UTC
Conditions: Adenoid Cystic Carcinoma
Interventions: Drug: Lutetium (177Lu) vipivotide tetraxetan
Sponsors: Maria Sklodowska-Curie National Research Institute of Oncology
Withdrawn -
Study of REM-422 in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
Posted: November 7th, 2023, 1:00am UTC
Conditions: Adenoid Cystic Carcinoma; Metastatic Adenoid Cystic Carcinoma; Recurrent Adenoid Cystic Carcinoma
Interventions: Drug: REM-422
Sponsors: Remix Therapeutics
Recruiting -
Study of OBT076 Associated or Not in Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma of the Head and Neck
Posted: July 5th, 2023, 11:00pm UTC
Conditions: Adenoid Cystic Carcinoma of the Head and Neck
Interventions: Drug: OBT076; Drug: Balstilimab
Sponsors: Groupe Oncologie Radiotherapie Tete et Cou
Completed -
A Phase 1/2 Study CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC
Posted: March 20th, 2023, 11:00pm UTC
Conditions: Adenoid Cystic Carcinoma; Metastatic Adenoid Cystic Carcinoma; Recurrent Adenoid Cystic Carcinoma
Interventions: Drug: CB-103; Drug: Abemaciclib; Drug: Lenvatinib
Sponsors: Glenn J. Hanna; Adenoid Cystic Carcinoma Research Foundation; Cellestia Biotech AG
Active, not recruiting -
Simultaneous Integrated Boost in Carbon Ion Radiotherapy for Head and Neck Adenoid Cystic Carcinoma
Posted: February 17th, 2023, 1:00am UTC
Conditions: Carcinoma, Adenoid Cystic; Head and Neck Cancer
Interventions: Radiation: simultaneous integrated boost of carbon ions radiation therapy
Sponsors: CNAO National Center of Oncological Hadrontherapy
Recruiting -
PSMA-PET Imaging of Salivary Gland Tumours and Other Rare Cancers
Posted: October 17th, 2022, 11:00pm UTC
Conditions: Salivary Gland Tumor; Rare Malignant Neoplasm
Interventions: Diagnostic Test: 68-Ga PSMA PET scan
Sponsors: National Cancer Centre, Singapore
Active, not recruiting -
A Study of XMT-1660 in Participants With Solid Tumors
Posted: May 17th, 2022, 11:00pm UTC
Conditions: Triple Negative Breast Cancer; Breast Cancer; Endometrial Cancer; Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cavity Cancer; Adenoid Cystic Carcinoma
Interventions: Drug: XMT-1660
Sponsors: Mersana Therapeutics
Recruiting -
A Study of SGN-B7H4V in Advanced Solid Tumors
Posted: January 18th, 2022, 1:00am UTC
Conditions: Ovarian Neoplasms; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Triple Negative Breast Neoplasms; HER2 Negative Breast Neoplasms; Hormone Receptor Positive Breast Neoplasms; Endometrial Neoplasms; Carcinoma, Non-Small-Cell Lung; Cholangiocarcinoma; Gallbladder Carcinoma; Adenoid Cystic Carcinoma
Interventions: Drug: SGN-B7H4V; Drug: Pembrolizumab
Sponsors: Seagen Inc.
Recruiting -
Amivantamab in Adenoid Cystic Carcinoma
Posted: October 12th, 2021, 11:00pm UTC
Conditions: Salivary Gland Cancer
Interventions: Drug: Amivantamab
Sponsors: Trisha Wise-Draper
Recruiting -
AL101 Before Surgery for the Treatment of Notch Activated Adenoid Cystic Cancer
Posted: July 22nd, 2021, 11:00pm UTC
Conditions: Adenoid Cystic Carcinoma; Metastatic Adenoid Cystic Carcinoma
Interventions: Drug: AL101; Procedure: Therapeutic Conventional Surgery
Sponsors: M.D. Anderson Cancer Center
Recruiting -
Pemetrexed and Pembrolizumab for the Treatment of Recurrent and/or Metastatic Salivary Gland Cancer
Posted: May 20th, 2021, 11:00pm UTC
Conditions: Metastatic Salivary Gland Carcinoma; Recurrent Salivary Gland Carcinoma; Stage IV Major Salivary Gland Cancer AJCC v8; Adenoid Cystic Carcinoma
Interventions: Biological: Pembrolizumab; Drug: Pemetrexed Disodium; Procedure: Biospecimen Collection; Procedure: Computed Tomography; Procedure: Positron Emission Tomography; Procedure: Magnetic Resonance Imaging; Procedure: PSMA PET Scan
Sponsors: Mayo Clinic
Recruiting -
Stereotactic Body Radiotherapy (SBRT) for Early Treatment of Oligometastatic Adenoid Cystic Carcinoma: the SOLAR Trial
Posted: May 12th, 2021, 11:00pm UTC
Conditions: Adenoid Cystic Carcinoma; Metastatic Adenoid Cystic Carcinoma
Interventions: Other: Standard of Care; Radiation: SBRT
Sponsors: Dana-Farber Cancer Institute; Adenoid Cystic Carcinoma Research Foundation; Gateway for Cancer Research
Recruiting -
A Dose Escalation and Cohort Expansion Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors or Non-Hodgkin Lymphoma
Posted: January 22nd, 2021, 1:00am UTC
Conditions: Relapsed Solid Tumors; Refractory Solid Tumors; Non-Hodgkin Lymphoma; HGSOC; Platinum Resistant High Grade Serous Ovarian Cancer
Interventions: Drug: KB-0742
Sponsors: Kronos Bio
Terminated -
P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) and Advanced Salivary Gland Cancers (SGC)
Posted: January 31st, 2020, 1:00am UTC
Conditions: Prostatic Neoplasms, Castration-Resistant; Neoplasms by Histologic Type; Neoplasms, Prostate; Prostate Cancer; Metastatic Castration-resistant Prostate Cancer; Neoplasms; Prostatic Neoplasms; Genital Neoplasms, Male; Urogenital Neoplasms; Neoplasms by Site; Prostatic Disease; Salivary Gland Cancer; Salivary Gland Tumor; Adenoid Cystic Carcinoma; Salivary Duct Carcinoma; Mucoepidermoid Carcinoma; Acinic Cell Tumor
Interventions: Biological: P-PSMA-101 CAR-T cells; Drug: Rimiducid
Sponsors: Poseida Therapeutics, Inc.
Terminated -
Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers
Posted: December 24th, 2019, 1:00am UTC
Conditions: Adenoid Cystic Carcinoma; Salivary Gland Cancer
Interventions: Drug: Lenvatinib; Drug: Pembrolizumab
Sponsors: Memorial Sloan Kettering Cancer Center; Merck Sharp & Dohme LLC; Eisai Inc.
Active, not recruiting -
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
Posted: October 28th, 2019, 11:00pm UTC
Conditions: Non Small Cell Lung Cancer; Advanced Solid Tumor; Metastatic Melanoma; Metastatic Head and Neck Carcinoma; Metastatic Renal Cell Carcinoma; Metastatic Colorectal Cancer; Sarcomas; Metastatic Prostate Cancer; Ovarian Cancer; Small Cell Lung Cancer; Metastatic Breast Cancer; Pancreas Cancer; Gastric Cancer; Esophageal Cancer; Gastroesophageal Junction Adenocarcinoma; Cervical Cancer; Adenoid Cystic Carcinoma; Salivary Gland Cancer; Urothelial Carcinoma
Interventions: Drug: ONC-392; Drug: Pembrolizumab; Drug: Docetaxel
Sponsors: OncoC4, Inc.; National Cancer Institute (NCI)
Recruiting -
A Study to Evaluate the Efficacy and Safety of Rivoceranib in Participants With Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC)
Posted: October 8th, 2019, 11:00pm UTC
Conditions: Adenoid Cystic Carcinoma
Interventions: Drug: Rivoceranib
Sponsors: Elevar Therapeutics
Terminated -
Axitinib and Avelumab in Treating Patients With Recurrent or Metastatic Adenoid Cystic Carcinoma
Posted: June 19th, 2019, 11:00pm UTC
Conditions: Metastatic Adenoid Cystic Carcinoma; Progressive Disease; Recurrent Adenoid Cystic Carcinoma
Interventions: Drug: Avelumab; Drug: Axitinib
Sponsors: M.D. Anderson Cancer Center; National Cancer Institute (NCI)
Completed -
APG-115 in Salivary Gland Cancer Trial
Posted: December 20th, 2018, 1:00am UTC
Conditions: Malignant Salivary Gland Cancer; Salivary Gland Cancer
Interventions: Drug: APG-115; Drug: Carboplatin
Sponsors: University of Michigan Rogel Cancer Center; Ascentage Pharma Group Inc.
Active, not recruiting -
A Study Of AL101In Patients With Adenoid Cystic Carcinoma (ACC) Bearing Activating Notch Mutations
Posted: October 1st, 2018, 11:00pm UTC
Conditions: Adenoid Cystic Carcinoma
Interventions: Drug: AL101
Sponsors: Ayala Pharmaceuticals, Inc,
Completed -
Innovative SolutIons for DosimEtry in Hadrontherapy (INSIDE)
Posted: September 7th, 2018, 11:00pm UTC
Conditions: Particle Therapy
Interventions: Radiation: carbon ions radiation therapy; Radiation: protons radiation therapy
Sponsors: CNAO National Center of Oncological Hadrontherapy
Recruiting -
Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
Posted: June 14th, 2018, 11:00pm UTC
Conditions: Head and Neck Carcinoma; Adenoid Cystic Carcinoma; Lung Cancer; Non-Small Cell Lung Cancer; Breast Cancer; Pancreatic Cancer; Mesothelioma; Thymic Carcinoma; Cervical Cancer; Ovarian Cancer; Bladder Cancer; Esophageal Cancer; Uterine Cancer; Sarcoma; Any Solid Tumors Progressed After a Prior Immunotherapy; Thymoma; Appendiceal Cancer; Olfactory Neuroblastoma
Interventions: Drug: VMD-928 300 mg Tablet (ongoing); 100 mg Capsule (complete)
Sponsors: VM Oncology, LLC
Recruiting -
Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies
Posted: February 6th, 2018, 1:00am UTC
Conditions: Breast Cancer; Colorectal Cancer; Adenoid Cystic Carcinoma; Non-hodgkin Lymphoma; Glomus Tumor, Malignant; Hepatocellular Carcinoma; Osteosarcoma; T-ALL
Interventions: Drug: CB-103
Sponsors: Cellestia Biotech AG
Terminated -
Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer
Posted: June 1st, 2017, 11:00pm UTC
Conditions: Salivary Gland Cancer
Interventions: Drug: Nivolumab; Drug: Ipilimumab
Sponsors: Memorial Sloan Kettering Cancer Center; Bristol-Myers Squibb
Active, not recruiting -
Nivolumab and Ipilimumab in Treating Patients With Metastatic/Recurrent ACC of All Sites and Non-ACC Salivary Gland Cancer
Posted: May 10th, 2017, 11:00pm UTC
Conditions: Major Salivary Gland Carcinoma; Minor Salivary Gland Carcinoma; Recurrent Salivary Gland Carcinoma; Stage IV Major Salivary Gland Carcinoma; Stage IVA Major Salivary Gland Carcinoma; Stage IVB Major Salivary Gland Carcinoma; Stage IVC Major Salivary Gland Carcinoma
Interventions: Biological: Ipilimumab; Other: Laboratory Biomarker Analysis; Biological: Nivolumab
Sponsors: Northwestern University; Bristol-Myers Squibb; National Cancer Institute (NCI)
Active, not recruiting -
Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers
Posted: December 1st, 2016, 1:00am UTC
Conditions: Adnexal Carcinoma; Anaplastic Large Cell Lymphoma, ALK-Negative; Anaplastic Large Cell Lymphoma, ALK-Positive; Apocrine Carcinoma; Carcinoma Arising From Cylindroma; Carcinoma Arising From Spiradenoma; Digital Papillary Adenocarcinoma; Endocrine Mucin-Producing Sweat Gland Carcinoma; Extramammary Paget Disease; Extraocular Sebaceous Carcinoma; Hidradenocarcinoma; Keratoacanthoma; Malignant Sweat Gland Neoplasm; Merkel Cell Carcinoma; Microcystic Adnexal Carcinoma; NK-Cell Lymphoma, Unclassifiable; Papillary Adenocarcinoma; Porocarcinoma; Primary Cutaneous Mucinous Carcinoma; Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma; Recurrent T-Cell Non-Hodgkin Lymphoma; Refractory Anaplastic Large Cell Lymphoma; Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma; Refractory Merkel Cell Carcinoma; Refractory Mycosis Fungoides; Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma; Refractory Skin Squamous Cell Carcinoma; Refractory T-Cell Non-Hodgkin Lymphoma; Sezary Syndrome; Signet Ring Cell Adenocarcinoma; Skin Adenoid Cystic Carcinoma; Skin Basal Cell Carcinoma; Skin Basosquamous Cell Carcinoma; Skin Squamous Cell Carcinoma; Squamoid Eccrine Ductal Carcinoma; Squamous Cell Carcinoma of Unknown Primary; Sweat Gland Carcinoma; Trichilemmal Carcinoma; Vulvar Squamous Cell Carcinoma
Interventions: Procedure: Biopsy; Procedure: Biospecimen Collection; Procedure: Computed Tomography; Other: Laboratory Biomarker Analysis; Biological: Nivolumab; Procedure: Positron Emission Mammography; Biological: Talimogene Laherparepvec
Sponsors: National Cancer Institute (NCI)
Active, not recruiting -
Study of Axitinib in Patients With Recurred or Metastatic Adenoid Cystic Carcinoma
Posted: August 8th, 2016, 11:00pm UTC
Conditions: Recurrent ACC, metastaticACC, Unreaectable ACC
Interventions: Drug: Axitinib; Other: Observation
Sponsors: Seoul National University Hospital
Completed -
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Posted: July 15th, 2016, 11:00pm UTC
Conditions: Acinar Cell Carcinoma; Adenoid Cystic Carcinoma; Adrenal Cortical Carcinoma; Adrenal Gland Pheochromocytoma; Anal Canal Neuroendocrine Carcinoma; Anal Canal Undifferentiated Carcinoma; Angiosarcoma; Apocrine Neoplasm; Appendix Mucinous Adenocarcinoma; Bartholin Gland Transitional Cell Carcinoma; Basal Cell Carcinoma; Bladder Adenocarcinoma; Breast Metaplastic Carcinoma; Cervical Adenocarcinoma; Cholangiocarcinoma; Chordoma; Colorectal Squamous Cell Carcinoma; Desmoid Fibromatosis; Endometrial Transitional Cell Carcinoma; Endometrioid Adenocarcinoma; Esophageal Neuroendocrine Carcinoma; Esophageal Undifferentiated Carcinoma; Extrahepatic Bile Duct Carcinoma; Extramammary Paget Disease; Fallopian Tube Adenocarcinoma; Fallopian Tube Transitional Cell Carcinoma; Fibromyxoid Tumor; Gallbladder Carcinoma; Gastric Neuroendocrine Carcinoma; Gastric Squamous Cell Carcinoma; Gastric Undifferentiated Carcinoma; Gastrointestinal Stromal Tumor; Gestational Trophoblastic Tumor; Giant Cell Carcinoma; Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type; Intestinal Neuroendocrine Carcinoma; Intrahepatic Cholangiocarcinoma; Lung Neuroendocrine Tumor; Lung Sarcomatoid Carcinoma; Major Salivary Gland Carcinoma; Malignant Neoplasm of Unknown Primary; Malignant Odontogenic Neoplasm; Malignant Peripheral Nerve Sheath Tumor; Malignant Solid Neoplasm; Malignant Testicular Sex Cord-Stromal Tumor; Metastatic Pituitary Neuroendocrine Tumor; Minimally Invasive Lung Adenocarcinoma; Mixed Mesodermal (Mullerian) Tumor; Mucinous Adenocarcinoma; Mucinous Cystadenocarcinoma; Nasal Cavity Adenocarcinoma; Nasal Cavity Carcinoma; Nasopharyngeal Carcinoma; Nasopharyngeal Low Grade Papillary Adenocarcinoma; Nasopharyngeal Undifferentiated Carcinoma; Oral Cavity Carcinoma; Oropharyngeal Undifferentiated Carcinoma; Ovarian Adenocarcinoma; Ovarian Germ Cell Tumor; Ovarian Mucinous Adenocarcinoma; Ovarian Squamous Cell Carcinoma; Ovarian Transitional Cell Carcinoma; Pancreatic Acinar Cell Carcinoma; Pancreatic Neuroendocrine Carcinoma; Paraganglioma; Paranasal Sinus Adenocarcinoma; Paranasal Sinus Carcinoma; Parathyroid Gland Carcinoma; PEComa; Penile Squamous Cell Carcinoma; Peritoneal Mesothelial Neoplasm; Placental Choriocarcinoma; Primary Peritoneal High Grade Serous Adenocarcinoma; Pseudomyxoma Peritonei; Rare Disorder; Scrotal Squamous Cell Carcinoma; Seminal Vesicle Adenocarcinoma; Seminoma; Serous Cystadenocarcinoma; Small Intestinal Adenocarcinoma; Small Intestinal Squamous Cell Carcinoma; Spindle Cell Neoplasm; Teratoma With Somatic-Type Malignancy; Testicular Non-Seminomatous Germ Cell Tumor; Thyroid Gland Carcinoma; Tracheal Carcinoma; Transitional Cell Carcinoma; Ureter Adenocarcinoma; Ureter Squamous Cell Carcinoma; Urethral Adenocarcinoma; Urethral Squamous Cell Carcinoma; Vaginal Adenocarcinoma; Vaginal Squamous Cell Carcinoma, Not Otherwise Specified; Vulvar Carcinoma
Interventions: Procedure: Biospecimen Collection; Procedure: Computed Tomography; Procedure: Echocardiography; Biological: Ipilimumab; Procedure: Magnetic Resonance Imaging; Biological: Nivolumab
Sponsors: National Cancer Institute (NCI)
Active, not recruiting -
An Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma
Posted: May 26th, 2016, 11:00pm UTC
Conditions: Neoplasms
Interventions: Drug: GSK3326595; Drug: Pembrolizumab
Sponsors: GlaxoSmithKline
Completed -
Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma
Posted: May 23rd, 2016, 11:00pm UTC
Conditions: Adenoid Cystic Carcinoma
Interventions: Drug: Lenvatinib
Sponsors: Memorial Sloan Kettering Cancer Center; Eisai Inc.
Active, not recruiting -
Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma
Posted: March 28th, 2014, 11:00pm UTC
Conditions: Adenoid Cystic Carcinoma
Interventions: Drug: Regorafenib
Sponsors: Memorial Sloan Kettering Cancer Center; Bayer
Completed -
Tissue Sample Collection From Patients With Head and Neck Cancer and From Healthy Participants
Posted: May 12th, 2009, 11:00pm UTC
Conditions: Head and Neck Cancer
Interventions: Other: biologic sample preservation procedure; Other: medical chart review
Sponsors: Vanderbilt University Medical Center; National Cancer Institute (NCI)
Recruiting